key: cord-1006825-sqoxt1ox authors: Kohler, P.; Guesewell, S.; Seneghini, M.; Egger, T.; Leal-Neto, O.; Brucher, A.; Lemmenmaier, E.; Moeller, C.; Rieder, P.; Ruetti, M.; Stocker, R.; Vuichard-Gysin, D.; Wiggli, B.; Besold, U.; Friedl, A.; Kuster, S.; McGeer, A.; Risch, L.; Schlegel, M.; Vernazza, P.; Kahlert, C. R. title: Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent Covid-19 -- a prospective multicentre cohort study date: 2021-06-12 journal: nan DOI: 10.1101/2021.06.09.21258422 sha: 9191871322b826ff6c51554eb5cb2d9f07cac904 doc_id: 1006825 cord_uid: sqoxt1ox Objectives In a prospective healthcare worker (HCW) cohort, we assessed the risk of SARS-CoV-2 infection according to baseline serostatus. Methods Baseline serologies were performed among HCW from 23 Swiss healthcare institutions between June and September 2020, before the second COVID-19 wave. Participants answered weekly electronic questionnaires covering information about nasopharyngeal swabs (PCR/rapid antigen tests) and symptoms compatible with Coronavirus Disease 2019 (COVID-19). Screening of symptomatic staff by nasopharyngeal swabs was routinely performed in participating facilities. We compared numbers of positive nasopharyngeal tests and occurrence of COVID-19 symptoms between HCW with and without anti-nucleocapsid antibodies. Results A total of 4'818 HCW participated, whereof 144 (3%) were seropositive at baseline. We analysed 107'820 questionnaires with a median follow-up of 7.9 months. Median number of answered questionnaires was similar (24 vs. 23 per person, P=0.83) between those with and without positive baseline serology. Among 2'713 HCW with [≥]1 SARS-CoV-2 test during follow-up, 3/67 (4.5%) seropositive individuals reported a positive result (one of whom asymptomatic), compared to 547/2646 (20.7%) seronegative participants, 12 of whom asymptomatic (risk ratio [RR] 0.22; 95% confidence interval [CI] 0.07 to 0.66). Seropositive HCWs less frequently reported impaired olfaction/taste (6/144, 4.2% vs. 588/4674, 12.6%, RR 0.33, 95%-CI: 0.15-0.73), chills (19/144, 13.2% vs. 1040/4674, 22.3%, RR 0.59, 95%-CI: 0.39-0.90), and limb/muscle pain (28/144, 19.4% vs. 1335/4674, 28.6%, RR 0.68 95%-CI: 0.49-0.95). Impaired olfaction/taste and limb/muscle pain also discriminated best between positive and negative SARS-CoV-2 results. Conclusions Having SARS-CoV-2 anti-nucleocapsid antibodies provides almost 80% protection against SARS-CoV-2 re-infection for a period of at least eight months. Objectives 57 In a prospective healthcare worker (HCW) cohort, we assessed the risk of SARS-CoV-2 58 infection according to baseline serostatus. [1] . Documented cases of reinfection (mean interval between infections was 106 days) are 95 increasing and alternative avenues for immunity to SARS-CoV-2 have been proposed [2] . 96 However, recent evidence suggests that neutralizing antibodies against SARS-CoV-2 are 97 stably detectable for at least 9 months and offer protection against clinically relevant (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Study design 109 We initiated a prospective cohort study in 23 healthcare institutions in Northern and Eastern 110 Switzerland. HCW with and without patient contact comprised the study population. Study 111 approval was granted by the ethics committee of Eastern Switzerland (#2020-00502). 112 Baseline results have been previously reported [6] . Upon study inclusion, participants provided blood for baseline serology. Subsequently, 114 participants were tested through nasopharyngeal swabs (NPS) as soon as they experienced 115 any COVID-19 compatible symptoms such as fever and/or the presence of any respiratory 116 symptom (i.e. shortness of breath, cough, or sore throat). This symptom-based screening (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Because previously seropositive participants might be tested less frequently than seronegative 152 HCW, we also compared the frequency of self-reported symptoms according to serostatus at 153 baseline among all study participants. For this analysis, questionnaires submitted within 2 154 weeks from baseline serology were excluded to avoid the detection of symptoms associated 155 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. ; https://doi.org/10.1101/2021.06.09.21258422 doi: medRxiv preprint with episodes, which had started before baseline. For each participant, we summarized a 156 symptom as present if reported in any of the submitted questionnaires, and absent otherwise; 157 risk ratios (and 95% CI) and proportion tests were calculated for each symptom. 158 To assess specificity of symptoms regarding SARS-CoV-2 infection, we compared the We recruited HCW (n=4'818) between 22 June and 20 October 2020 ( Table 1) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. HCWs was asymptomatic at time of re-infection. For detailed characteristics, see Table 2 . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. symptoms which discriminated best between episodes with positive and negative 208 SARS-CoV-2 nasopharyngeal test were impaired olfaction/taste (OR 22.2 95%-CI: 17.1-29.1, 209 P<0.001), limb/muscle pain (OR 4.7 95%-CI: 3.8-5.9, P<0.001), and weakness (OR 4.4 95%-210 CI: 3.1-6.4, P<0.001) (Figure 3, Table S1 ). 211 For validation of swab results, we cross-checked self-reported test results for a subgroup of (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. ; https://doi.org/10.1101/2021.06.09.21258422 doi: medRxiv preprint of natural infection against reinfection was above 90% [9]. Also, data from a population-234 based study (>500'000 people) conducted in Denmark suggest that protection after natural 235 SARS-CoV-2 infection was 80% after 6 months (but only 47% for adults aged 65 years or 236 older) [10] . A retrospective propensity-score matched cohort study from Western Switzerland Previous studies have mainly looked at the incidence of confirmed SARS-CoV-2 infection to 249 assess the risk of re-infection. This approach has the inherent limitation that people who are 250 seropositive might be less likely to undergo testing, as seen in our data. In addition to testing 251 for SARS-CoV-2, we therefore used a second approach to assess the protective effect of 252 seropositivity on subsequent COVID-19. Using weekly symptom frequency as proxy for 253 COVID-19 allows comparing incidence of COVID-19 irrespective of whether patients 254 underwent testing or not. Of course, this signal is being diluted by infections caused by other 255 respiratory viruses, especially for symptoms like coryza, sore throat, cough or fever. 256 However, certain symptoms such as loss of taste or smell and myalgias have already been 257 shown by others to be more specific for COVID-19 [15, 16] . The fact that exactly these 258 symptoms occurred less frequently among those with antibodies at baseline supports our 259 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. ; https://doi.org/10.1101/2021.06.09.21258422 doi: medRxiv preprint finding of a reduced risk for SARS-CoV-2 re-infection in this group. A limitation of this 260 approach is that some participants might suffer from persisting COVID-19 symptoms (i.e. A limitation of our study is the fact that nasopharyngeal SARS-CoV-2 testing was not 282 routinely performed. Therefore, asymptomatic carriage of SARS-CoV-2 cannot be excluded 283 in those with antibodies at baseline. We also determined SARS-CoV-2 anti-nucleocapsid 284 antibody titers and not anti-spike antibodies, which have been shown to correlate better with 285 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. or even more frequently[23] than anti-S antibodies. We therefore suggest that our results 287 represent, or somewhat underestimate the true protective effect mediated by anti-S antibodies. 288 Swab results and symptoms were self-reported. Because validation of some of the swab 289 results showed mostly consistent results, we consider these self-reported data to be highly 290 reliable. Furthermore, we cannot definitely confirm that the three seropositive HCWs with 291 positive SARS-CoV-2 NPS were indeed re-infected with a new strain. However, the long 292 latency between the episodes, new onset of symptoms (two cases), and a negative PCR 293 between episodes (one case) strongly support our hypothesis of re-infection (rather than 294 persistence of viral RNA for more than 6 months). Another shortcoming of this study is that 295 SARS-CoV-2 specific cellular immunity was not evaluated. This is mainly due to the fact that 296 these measurements are still very time-consuming and cost-intensive in a large population. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All authors contributed to the conceptualization of the study. PK and CRK supervised the 327 study. PK, OL, TE, PV and CRK were responsible for data curation. TE was responsible for (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 12, 2021. also Table S1 ). SARS-CoV-2 immunity and reinfection Prospects for durable 338 immune control of SARS-CoV-2 and prevention of reinfection Neutralizing 341 Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel 342 Outbreak with a High Attack Rate Antibody Status 345 and Incidence of SARS-CoV-2 Infection in Health Care Workers Seroprevalence and humoral immune durability 348 of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional 349 study Non-occupational and 351 occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers -352 A multicentre cross-sectional study Covid-19: Two antibody tests are "highly specific" but vary in sensitivity, evaluations 355 find CoV-2 Seropositive Antibody Test With Risk of Future Infection SARS-CoV-2 360 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 Assessment of protection against 363 reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a 364 population-level observational study Risk of reinfection after 367 seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study SARS-CoV-2 infection rates of 370 antibody-positive compared with antibody-negative health-care workers in England: a large, 371 multicentre, prospective cohort study (SIREN) Risk of SARS-CoV-2 reinfection in a university student population Neutralizing antibody 376 levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Real-time tracking of 379 self-reported symptoms to predict potential COVID-19 Neurological manifestations 382 of COVID-19: a systematic review Features of 385 anosmia in COVID-19 COVID-19 re-infection by a 388 phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing Confirmed 391 Reinfection with SARS-CoV-2 Variant VOC-202012/01 Safety and Efficacy of 395 the BNT162b2 mRNA Covid-19 Vaccine Serological 398 surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public 399 health workers Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four 402 automated immunoassays and three ELISAs Immunological memory to SARS-405 Prior COVID-408 19 protects against reinfection, even in the absence of detectable antibodies Exposure to SARS-CoV-2 generates T-cell 411 memory in the absence of a detectable viral infection No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity